Table 1 Baseline demographic and clinical characteristics of ART-experienced, virologically suppressed PWH switching to DTG/3TC, BIC/FTC/TAF, or a DTG 3DR between 01MAY2019 and 31OCT2020 (N = 8,037)
|  | DTG/3TCa (N = 1,450) | BIC/FTC/TAFb (N = 5,691) | DTG 3DRc (N = 896) |
|---|---|---|---|
Age, Median (IQR) | 45 (34, 55) | 43 (32, 54) | 43 (32, 53) |
Sex, n (%) | Â | Â | Â |
 Female | 271 (19) | 909 (16) | 163 (18) |
Race, n (%) | Â | Â | Â |
 Asian | 36 (3) | 100 (2) | 11 (1) |
 Black | 508 (35) | 2,456 (43) | 438 (49) |
 White | 802 (55) | 2,752 (48) | 376 (42) |
 Mixed race or other race | 52 (4) | 196 (3) | 40 (5) |
 Unknown | 52 (4) | 187 (3) | 31 (4) |
Ethnicity, n (%) | Â | Â | Â |
 Hispanic | 376 (26) | 1,368 (24) | 148 (17) |
 Not Hispanic | 1,014 (70) | 4,138 (73) | 723 (81) |
 Unknown | 60 (4) | 185 (3) | 25 (3) |
Geographic Region, n (%) | Â | Â | Â |
 US Midwest | 25 (2) | 259 (5) | 35 (4) |
 US Northeast | 91 (6) | 602 (11) | 116 (13) |
 US South | 778 (54) | 3,901 (69) | 665 (74) |
 US West | 555 (38) | 892 (16) | 74 (8) |
 US Territories | ≤ 5d | 37 (1) | 6 (1) |
Payer, n (%) | Â | Â | Â |
 Medicare | 154 (11) | 441 (8) | 90 (10) |
 Medicaid | 355 (25) | 1,242 (22) | 161 (18) |
 Commercial Insurance | 761 (53) | 2,685 (47) | 384 (43) |
 Ryan White / ADAP | 469 (32) | 1,879 (33) | 304 (34) |
 Cash | 11 (1) | 66 (1) | ≤ 5d |
 No payer data available | 87 (6) | 501 (9) | 109 (12) |
Core agent class of regimen immediately prior to baseline, n (%) | Â | Â | Â |
 INSTI | 1,062 (73) | 2,522 (44) | 117 (13) |
 NNRTI | 127 (9) | 823 (15) | 52 (6) |
 PI | 57 (4) | 421 (7) | 57 (6) |
 Entry inhibitor | ≤ 5d | ≤ 5d | 0 (0) |
 Unknown | 99 (7) | 1,718 (30) | 635 (71) |
 > 1 core agent | 104 (7) | 203 (4) | 35 (4) |
CD4 cell count (cells/µL) |  |  |  |
 CD4 count test result available | 1,442 (99) | 5,603 (99) | 878 (98) |
 Median cells/µL (IQR) | 730 (550, 944) | 675 (484, 892) | 678 (471, 861) |
Any comorbiditiese, n (%) | 1,126 (78) | 4,054 (71) | 548 (61) |